RNAC
Cartesian Therapeutics, Inc.
$5.84
-10.84%
$171.6M
No data for this timeframe.
Vol
Market Cap$171.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders8 funds
Inst. Value$16.0M
Inst. Activity4 buys / 1 sells
Reddit Sentiment67° Warm
SEC Reports1
Press Releases1
Recent Activity
Jun 5, 2026
SEC
Cartesian Therapeutics secured a senior secured credit facility from K2 HealthVentures for up to $150 million, with an i
8-K — Impact 7/10
Apr 2, 2026
Insider
Kalayoglu Murat sold 758,001 shares
10%+ Owner @ $0.00 ($0.00)
Apr 2, 2026
Insider
Kalayoglu Murat sold 22,740.03 shares
10%+ Owner @ $0.00 ($0.00)
Apr 2, 2026
Insider
Hoge Elizabeth sold 758,001 shares
10%+ Owner @ $0.00 ($0.00)
Inst.
FMR LLC — TRIM
1,366,989 shares ($9.9M)
Inst.
BANK OF AMERICA CORP — DOUBLED
113,092 shares ($815.4K)
May 26, 2026
Press
Cartesian Therapeutics secured a $150M non-dilutive credit facility from K2 HealthVentures, with an initial $50M tranche
Impact 7/10
May 26, 2026
fda
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
<p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; f
Price Targets
$34.57
+492.0% upside
Strong Buy
Current $5.84
Low $16.00
Median $39.00
High $44.00
7 analysts
$16.00
$44.00
Analyst Ratings
5Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| May 26, 2026 | Needham | MAINTAIN | Buy → Buy |
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 1, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Mar 10, 2026 | Wedbush | REITERATE | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.65 ▲ +4.4% | $-0.65 — $-0.65 | 16% YoY | 1 |
| Next Q | $-0.69 ▼ -53.3% | $-0.69 — $-0.69 | 6% YoY | 1 |
| Current FY | $-3.35 ▼ -55.8% | $-3.35 — $-3.35 | 33% YoY | 1 |
| Next FY | $-2.68 ▼ -58.6% | $-2.68 — $-2.68 | 20% YoY | 1 |
Latest Reports
BULLISH
8-K
7/10
Cartesian Therapeutics secured a senior secured credit facility from K2 HealthVentures for up to $150 million, with an i
Jun 5, 2026
BULLISH
Press
7/10
Cartesian Therapeutics secured a $150M non-dilutive credit facility from K2 HealthVentures, with an initial $50M tranche
May 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $9.9M | TRIM |
| VANGUARD GROUP INC | $3.9M | — |
| BANK OF AMERICA CORP | $815.4K | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $658.1K | NEW |
| RENAISSANCE TECHNOLOGIES LLC | $296.3K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 2, 2026 | Kalayoglu Murat | M | $0.00 |
| Apr 2, 2026 | Kalayoglu Murat | M | $0.00 |
| Apr 2, 2026 | Hoge Elizabeth | M | $0.00 |
| Apr 2, 2026 | Hoge Elizabeth | M | $0.00 |
| Mar 13, 2026 | Singer Michael | G | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
8 institutional holders with $16.0M total value (2,214,043 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, BANK. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 1,366,989 | $9.9M | 61.7% | TRIM -36.6% |
| 2 | VANGUARD GROUP INC | 541,228 | $3.9M | 24.4% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 113,092 | $815.4K | 5.1% | DOUBLED +703.8% |
| 4 | TWO SIGMA INVESTMENTS, LP | 91,278 | $658.1K | 4.1% | NEW |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 41,100 | $296.3K | 1.9% | NEW |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 25,300 | $182.4K | 1.1% | ADD +40.7% |
| 7 | MORGAN STANLEY | 23,294 | $167.9K | 1.1% | TRIM -35.0% |
| 8 | WELLS FARGO & COMPANY/MN | 11,762 | $84.8K | 0.5% | ADD +49.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | TRIM | 2,155,783 | 1,366,989 | -36.6% | $9.9M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 14,069 | 113,092 | +703.8% | $815.4K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 91,278 | — | $658.1K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 41,100 | — | $296.3K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 7,884 | 11,762 | +49.2% | $84.8K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 29,213 | 18,974 | -35.0% | $193.9K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 5,833 | 7,884 | +35.2% | $80.6K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 19,500 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 17,850 | 29,213 | +63.7% | $303.5K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 19,500 | — | $202.6K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 5,981 | 13,933 | +133.0% | $144.8K | 2025-Q2 |
| UBS Group AG | TRIM | 31,118 | 13,206 | -57.6% | $137.2K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 11,015 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 315,000 | 147,297 | -53.2% | $1.9M | 2025-Q1 |
| UBS Group AG | ADD | 17,580 | 31,118 | +77.0% | $410.1K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 24,262 | 17,850 | -26.4% | $235.3K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 13,800 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 19,048 | 26,803 | +40.7% | $480.0K | 2024-Q4 |
| UBS Group AG | DOUBLED | 5,339 | 17,580 | +229.3% | $314.9K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 13,800 | — | $247.2K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 2,279 | 4,847 | +112.7% | $86.8K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 7,247 | 22,011 | +203.7% | $354.8K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 19,048 | — | $307.1K | 2024-Q3 |
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | Kalayoglu Murat | 10%+ Owner | M | 758,001 | $0.00 | $0.00 |
| Apr 2, 2026 | Kalayoglu Murat | 10%+ Owner | M | 22,740.03 | $0.00 | $0.00 |
| Apr 2, 2026 | Hoge Elizabeth | 10%+ Owner | M | 758,001 | $0.00 | $0.00 |
| Apr 2, 2026 | Hoge Elizabeth | 10%+ Owner | M | 22,740.03 | $0.00 | $0.00 |
| Mar 13, 2026 | Singer Michael | Director | G | 6,555 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 5 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$34.57 mean target
+492.0% upside
Strong Buy (1.13)
$16.00 Low
$44.00 High
| Metric | Value |
|---|---|
| Current Price | $5.84 |
| Target Low | $16.00 |
| Target Mean | $34.57 |
| Target Median | $39.00 |
| Target High | $44.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.13) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.65 | $-0.65 | $-0.65 | 15.8% | +4.4% | 1↑ 0↓ | $0.0B | -45.9% | 1 |
| Next Q 2026-09-30 |
$-0.69 | $-0.69 | $-0.69 | 5.6% | -53.3% | 0↑ 1↓ | $0.0B | -64.3% | 1 |
| Current FY 2026-12-31 |
$-3.35 | $-3.35 | $-3.35 | 32.9% | -55.8% | 0↑ 1↓ | $0.0B | -80.3% | 1 |
| Next FY 2027-12-31 |
$-2.68 | $-2.68 | $-2.68 | 20.0% | -58.6% | 0↑ 1↓ | $0.0B | -27.3% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.650 | |
| 7d ago | $-0.770 | +0.120 |
| 30d ago | $-0.680 | +0.030 |
| 60d ago | $-0.680 | +0.030 |
| 90d ago | $0.000 | -0.650 |
4 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| May 26, 2026 | Needham | MAINTAIN | Buy | Buy |
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 1, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 10, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 9, 2026 | Cantor Fitzgerald | UPGRADE | Neutral | Overweight |
| Mar 9, 2026 | Needham | REITERATE | Buy | Buy |
| Jan 9, 2026 | Needham | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% | |
| Apr 1, 2026 | 5 | 7 | 3 | 0 | 0 | 80% | |
| Mar 1, 2026 | 5 | 7 | 3 | 0 | 0 | 80% | |
| Feb 1, 2026 | 5 | 7 | 3 | 0 | 0 | 80% | |
| Jan 1, 2026 | 5 | 7 | 3 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 26, 2026
fda
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
<p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends
May 12, 2026
other
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
<p align="justify">FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-sta
May 7, 2026
earnings_calendar
RNAC Q1 2026 Earnings Scheduled — 2026-05-07
May 4, 2026
other
Cartesian Therapeutics Announces New Employment Inducement Grants
<p align="justify">FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-sta
Apr 30, 2026
earnings
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis </em></p>
Apr 2, 2026
other
Cartesian Therapeutics Announces New Employment Inducement Grants
<p align="justify">FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-s
Mar 11, 2026
earnings_calendar
RNAC Q4 2025 Earnings After Market Close — 2026-03-11
Mar 9, 2026
earnings
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
<p align="center"><em>Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis</em></p>
Mar 5, 2026
earnings_calendar
RNAC Q4 2025 Earnings After Market Close — 2026-03-05